Titan Pharmaceuticals, Inc. Accounts and Financing Receivable, after Allowance for Credit Loss
Titan Pharmaceuticals, Inc. had Accounts and Financing Receivable, after Allowance for Credit Loss of $1.00 million as of 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Balance Sheet › Assets
us-gaap:AccountsAndNotesReceivableNet · last filed 2025-03-20
- 2023-12-31: Accounts and Financing Receivable, after Allowance for Credit Loss $1.00M.
- 2023-09-30: Accounts and Financing Receivable, after Allowance for Credit Loss $1.50M.
| Period end | Accounts and Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2023-12-31 | $1.00M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.50M 10-K · filed 2024-04-01 |